Physician profile
Manuel Gonzalez
NPI 1801193701
$46,324.61
in general payments reported to CMS, 2019-2025
42 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $225 · 2021: $519 · 2022: $391 · 2023: $1,334 · 2024: $1,464 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,070.30 |
| Education | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bristol Myers Squibb Company | $40,615.38 | 2019 | |
| Abbvie INC. | $1,173.33 | 2019-2025 | |
| Janssen Biotech, INC. | $706.64 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $626.55 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.99 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $464.99 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $274.90 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $169.50 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $144.26 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $131.29 | 2024-2025 | Resmetirom, Rezdiffra |
| Pfizer INC. | $120.48 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $98.02 | 2023-2025 | Ocaliva |
| Bayer Healthcare Pharmaceuticals INC. | $95.15 | 2021-2025 | |
| Gilead Sciences, INC. | $89.93 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $81.23 | 2019-2024 | Dificid |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.